CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 407 enrolled
Drug / intervention
liraglutide +3 moredrug
Likely dose
liraglutide 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01907854
NCT01907854Phase 4Completed
CompareCT.gov

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Novo Nordisk A/S·interventional·Posted Jul 25, 2013·Updated Oct 2, 2018

In Brief

A Phase 4 clinical trial evaluating liraglutide, sitagliptin, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 407 participants across 106 sites in 7 countries.

Detailed Summary

This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCanada, Hungary, India, Israel, Puerto Rico, Spain, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 25, 2013
Enrollment StartDec 2, 2013
Primary CompletionJun 15, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.9 years ago

Interventions

liraglutidedrug

Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)

sitagliptindrug

100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)

placebodrug

Sitagliptin placebo tablets once-daily

placebodrug

Sitagliptin placebo tablets once-daily